Resverlogix Corp
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a bromodomain and extra-terminal (BET) inhibitor, selective for bromodomain 2. The activity of apabetalone impacts several important biological processes that drive risk in vascular disease patients, with important benefits for patients with cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney diseas (CKD), end-stage renal disease, neurodegenerative disease, and other orphan diseases. Apabetalone is in a Phse 3 tiral, BETonMACE, in high-risj CVD patients with type 2 DM and low levels of high-density lipoprotein. The company expects to initiate two Phase 2 trials in the coming yes; one in kidney dialysis and one in Fabry Disease. Both trials will evaluate biomarker changes and safety parameters in these patient populations
Delegate Contacts
Donald McCaffrey is President & Chief Executive Officer of Resverlogix Corp. Don has over 35years of corporate management experience, including over 17 years in drug discovery & development. Don co-founded Resverlogix in 2001 with Dr. Norman Wong. Don’s expertise in corporate operations has attracted an international team of experts to Resverlogix, including world renowned Key Opinion Leaders in the fields of cardiology, endocrinology and nephrology. Lead drug, apabetalone (RVX-208) is well into a Phase 3 clinical trial called 'BETonMACE.' Apabetalone has an 8 year lead on the market as the first epigenetic drug for the reduction of Major Adverse Cardiac Events (MACE). Don has strategically directed Resverlogix in its continued partnering discussions with global pharmaceutical companies, establishing one of the largest China biotech partnerships to date with Shenzhen Hepalink Pharmaceuticals